Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil and cognitive status after electroconvulsive therapy in major depressive patients
IRCT201608086280N10Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of remifentanil in major depressive disorder (MDD) (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Mini-Mental State Examination after electroconvulsive therapy. Started Sep 2016; status: completed.
02
Drugs
remifentanil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT201608086280N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201608086280N10.